US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SPYRE THERAPEUTICS INC

15.11

+0.45003.07%

Post-market: 15.110.00000.00%16:24 EDT

Volume:499.90K

Turnover:7.61M

Market Cap:910.76M

PE:-4.75

High:15.63

Open:14.95

Low:14.66

Close:14.66

Loading ...

Overview Company News Filings

Wall Street Set to Open Sharply Higher Wednesday on Positive Inflation Data

MT Newswires Live

Stifel Nicolaus Keeps Their Buy Rating on Spyre Therapeutics (SYRE)

Spyre Therapeutics Inc - Anticipates Cash Runway Into Second Half of 2028

THOMSON REUTERS

Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Says it will be Added to Nasdaq Biotechnology Index

MT Newswires Live

BRIEF-Spyre Therapeutics Added To The Nasdaq Biotechnology Index

Spyre Therapeutics Added to the Nasdaq Biotechnology Index

THOMSON REUTERS

Spyre Therapeutics Added to the Nasdaq Biotechnology Index

TD says Spyre has ‘superior TL1A program’ after Teva data

JonesTrading Initiates Spyre Therapeutics at Hold

MT Newswires Live

Spyre Therapeutics initiated with a Hold at JonesResearch

Spyre Therapeutics Announces Grants of Inducement Awards

BRIEF-Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies

Spyre Therapeutics Inc - Interim Data for Spy002 Molecules Expected in Q2 2025

THOMSON REUTERS

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-Life Extended Anti-Tl1a Antibodies

THOMSON REUTERS

Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Sector Update: Health Care Stocks Lean Lower Premarket Tuesday

MT Newswires Live

Spyre Therapeutics Prices $200 Million Common Stock Offering

MT Newswires Live

BRIEF-Spyre Therapeutics Announces Pricing Of $200 Mln Public Offering Of Common Stock At $27.50 Per Share

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SYRE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SYRE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SYRE\",,,,,undefined,":{"symbol":"SYRE","market":"US","secType":"STK","nameCN":"SPYRE THERAPEUTICS INC","latestPrice":15.11,"timestamp":1746216000000,"preClose":14.66,"halted":0,"volume":499897,"hourTrading":{"tag":"盘后","latestPrice":15.11,"preClose":15.11,"latestTime":"16:24 EDT","volume":11745,"amount":177466.68,"timestamp":1746217480365},"delay":0,"floatShares":46620090,"shares":60275561,"eps":-3.180151,"marketStatus":"Market Closed","change":0.45,"latestTime":"05-02 16:00:00 EDT","open":14.95,"high":15.63,"low":14.66,"amount":7606820.121358,"amplitude":0.066166,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.180151,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746432000000},"marketStatusCode":7,"adr":0,"listingDate":1460001600000,"exchange":"NASDAQ","adjPreClose":14.66,"preHourTrading":{"tag":"盘前","latestPrice":15.47,"preClose":14.66,"latestTime":"09:28 EDT","volume":855,"amount":12451.897665,"timestamp":1746192480030},"postHourTrading":{"tag":"盘后","latestPrice":15.11,"preClose":15.11,"latestTime":"16:24 EDT","volume":11745,"amount":177466.68,"timestamp":1746217480365},"volumeRatio":1.1434873669196768,"impliedVol":1.3561,"impliedVolPercentile":0.888},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SYRE\",,,,,undefined,":{"symbol":"SYRE","floatShares":46620090,"roa":"-27.43%","roe":"-59.28%","lyrEps":-3.180151,"volumeRatio":1.1434873669196768,"shares":60275561,"dividePrice":0,"high":15.63,"amplitude":0.066166,"preClose":14.66,"low":14.66,"week52Low":10.91,"pbRate":"2.52","week52High":40.49,"institutionHeld":0,"latestPrice":15.11,"eps":-3.180151,"divideRate":0,"volume":499897,"delay":0,"ttmEps":-3.180151,"open":14.95,"prevYearClose":23.28,"prevWeekClose":14.13,"prevMonthClose":15.23,"prevQuarterClose":16.135,"fiveDayClose":14.13,"twentyDayClose":13.99,"sixtyDayClose":23.56},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SYRE\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2503644214","title":"Wall Street Set to Open Sharply Higher Wednesday on Positive Inflation Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2503644214","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503644214?lang=en_us&edition=fundamental","pubTime":"2025-01-15 22:20","pubTimestamp":1736950829,"startTime":"0","endTime":"0","summary":"US stocks look set to open sharply higher in Wednesday's trading session as investor sentiment was buoyed by encouraging inflation data released earlier in the morning.Dow Jones Industrial Average fut","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OSTX","BK4077","LICY","SGBX","BK4129","PBHC","VMAR","FUND","BK4120","BK4023","MITQ","BK4190","LIF","BK4108","BK4139","BK4211","SYRE","BK4539","GIFT"],"gpt_icon":1},{"id":"2503456956","title":"Stifel Nicolaus Keeps Their Buy Rating on Spyre Therapeutics (SYRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2503456956","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503456956?lang=en_us&edition=fundamental","pubTime":"2025-01-14 09:10","pubTimestamp":1736817017,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Alex Thompson CFA from Stifel Nicolaus reiterated a Buy rating on Spyre Therapeutics (SYRE – Research Report). The ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-spyre-therapeutics-syre?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-spyre-therapeutics-syre?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYRE","SF"],"gpt_icon":0},{"id":"2503301460","title":"Spyre Therapeutics Inc - Anticipates Cash Runway Into Second Half of 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2503301460","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503301460?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:21","pubTimestamp":1736774510,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nFWN3O90QT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2503302193","title":"Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts","url":"https://stock-news.laohu8.com/highlight/detail?id=2503302193","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503302193?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:00","pubTimestamp":1736773200,"startTime":"0","endTime":"0","summary":"Phase 1 interim results expected for SPY002, two distinct extended half-life TL1A antibodies, in 2Q2025. Phase 1 interim results expected for SPY003, an extended half-life IL-23 antibody, in 2H2025. Phase 2 platform trial in ulcerative colitis  remains on track for initiation in mid-2025 with SPY001 , followed by SPY002 , SPY003 , and combinations thereof, with initial results expected in 2026. Strong balance sheet with preliminary cash, cash equivalents, and marketable securities balance of over $600M as of December 31, 2024*, anticipated to provide cash runway into the second half of 2028","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-highlights-2025-priorities-130000578.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-highlights-2025-priorities-130000578.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4139","SYRE","RA","IBD"],"gpt_icon":0},{"id":"2500127227","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2500127227","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500127227?lang=en_us&edition=fundamental","pubTime":"2025-01-04 06:20","pubTimestamp":1735942800,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Jan. 3, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc.  , a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease , today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 21,000 shares of common stock of Spyre to one non-executive employee as an equity inducement award under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended . The stock options were approved on January 2, 2025 and were material to the employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635.Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease  products by combining best-in-class antibody engineering, rational therap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-222000096.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-222000096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IBD","SYRE","BK4139","LENZ"],"gpt_icon":0},{"id":"2492389186","title":"Spyre Therapeutics Says it will be Added to Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492389186","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492389186?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:53","pubTimestamp":1734530001,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics  said Wednesday it will be added to the Nasdaq Biotechnology Index before trading begins Dec. 23.The company said the NBI tracks the performance of biotechnology and pharmaceutical companies listed on the Nasdaq stock exchange.Shares of the company were down 2% in recent Wednesday premarket activity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4112","NDAQ","QLD","USAW.SI","BK4585","MNQmain","IE00BGHQF748.EUR","IE00B64PRP62.GBP","SYRE","TQQQ","BK4139","NQmain","TSYW.SI","USJW.SI","LU2210150020.SGD","QID","PSQ","IE00B3QW5Z07.USD","LU2210149790.SGD","SQQQ",".IXIC","LU2095319765.USD","NVIW.SI","LENZ","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2492185654","title":"BRIEF-Spyre Therapeutics Added To The Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492185654","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492185654?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:34","pubTimestamp":1734528878,"startTime":"0","endTime":"0","summary":"BRIEF-Spyre Therapeutics Added To The Nasdaq Biotechnology IndexDec 18 (Reuters) - Nasdaq Inc NDAQ.O:SPYRE THERAPEUTICS ADDED TO THE NASDAQ BIOTECHNOLOGY INDEXSource text: ID:nPn8Ss0lRaFurther company coverage: NDAQ.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA1D6D98:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4139","IE00B64PRP62.GBP","BK4588","NDAQ","SYRE","LU2095319765.USD","BK4585","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4112","LU2210149790.SGD"],"gpt_icon":0},{"id":"2492164188","title":"Spyre Therapeutics Added to the Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492164188","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492164188?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:00","pubTimestamp":1734526804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA1D6D98:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4139","IE00BGHQF748.EUR","BK4112","BK4588","NDAQ","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU2210150020.SGD","SYRE","IE00B3QW5Z07.USD","LU2210149790.SGD","LU2095319765.USD"],"gpt_icon":0},{"id":"2492018392","title":"Spyre Therapeutics Added to the Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492018392","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492018392?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:00","pubTimestamp":1734526800,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Dec. 18, 2024 /PRNewswire/ --Spyre Therapeutics, Inc. , a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease , today announced Spyre has been added to the Nasdaq Biotechnology Index , effective prior to market open, Monday, December 23, 2024.For more information about the Nasdaq Biotechnology Index, please visit this link.Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease  products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com.Follow Spyre Therapeutics on social media: @spyretx and LinkedIn","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OF7quuu2hXwKuKaISmsaxw--~B/aD05Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/b47b05eb14d0fa90aed91f47beedafa6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OF7quuu2hXwKuKaISmsaxw--~B/aD05Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/b47b05eb14d0fa90aed91f47beedafa6"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-added-nasdaq-biotechnology-130000760.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-added-nasdaq-biotechnology-130000760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2095319765.USD","USJW.SI","BK4139","TSYW.SI","LU2210150020.SGD","IBD","NVIW.SI","IE00BGHQF748.EUR","USAW.SI","SYRE","SQQQ","NDAQ","QID","BK4112","BK4585","IE00B3QW5Z07.USD","TQQQ","IE00B64PRP62.GBP","QLD","MNQmain","LU2210149790.SGD","NQmain","LENZ","IE00BKPKM429.USD","PSQ","BK4588",".IXIC"],"gpt_icon":1},{"id":"2492994931","title":"TD says Spyre has ‘superior TL1A program’ after Teva data","url":"https://stock-news.laohu8.com/highlight/detail?id=2492994931","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492994931?lang=en_us&edition=fundamental","pubTime":"2024-12-18 03:20","pubTimestamp":1734463218,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren recommends buying shares of Spyre Therapeutics (SYRE) following the “impressive results” from Teva (TEVA) and Sano...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/td-says-spyre-has-superior-tl1a-program-after-teva-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/td-says-spyre-has-superior-tl1a-program-after-teva-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","BK4007","TEVA","TD","BK4588","BK4596","BK4139","BK4566","SYRE","BK4585","BK4557","BK4584","BK4559"],"gpt_icon":0},{"id":"2490385753","title":"JonesTrading Initiates Spyre Therapeutics at Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2490385753","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490385753?lang=en_us&edition=fundamental","pubTime":"2024-12-11 21:39","pubTimestamp":1733924348,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics, Inc (SYRE) has an average rating of buy and mean price target of $58.62, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from m","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","SYRE","LENZ"],"gpt_icon":0},{"id":"2490021958","title":"Spyre Therapeutics initiated with a Hold at JonesResearch","url":"https://stock-news.laohu8.com/highlight/detail?id=2490021958","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490021958?lang=en_us&edition=fundamental","pubTime":"2024-12-11 05:21","pubTimestamp":1733865692,"startTime":"0","endTime":"0","summary":"JonesResearch initiated coverage of Spyre Therapeutics (SYRE) with a Hold rating and no price target Spyre is a clinical-stage biotech developing h...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-initiated-with-a-hold-at-jonesresearch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-initiated-with-a-hold-at-jonesresearch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","SYRE"],"gpt_icon":0},{"id":"2488969417","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2488969417","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488969417?lang=en_us&edition=fundamental","pubTime":"2024-12-03 06:03","pubTimestamp":1733176980,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Dec. 2, 2024 /PRNewswire/ --Spyre Therapeutics, Inc.  , a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease , today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 45,000 shares of common stock of Spyre to three non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended . The stock options were approved on December 2, 2024 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635.Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease  products by combining best-in-class antibody engineerin","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OF7quuu2hXwKuKaISmsaxw--~B/aD05Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/b47b05eb14d0fa90aed91f47beedafa6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OF7quuu2hXwKuKaISmsaxw--~B/aD05Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/b47b05eb14d0fa90aed91f47beedafa6"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-220300749.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-announces-grants-inducement-220300749.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IBD","LENZ","SYRE"],"gpt_icon":0},{"id":"2488679940","title":"BRIEF-Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2488679940","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488679940?lang=en_us&edition=fundamental","pubTime":"2024-12-02 21:30","pubTimestamp":1733146234,"startTime":"0","endTime":"0","summary":"BRIEF-Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A AntibodiesDec 2 (Reuters) - Spyre Therapeutics Inc SYRE.O:SPYRE THERAPEUTICS ANNOUNC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241202:nTUA78VN12:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2488767655","title":"Spyre Therapeutics Inc - Interim Data for Spy002 Molecules Expected in Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2488767655","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488767655?lang=en_us&edition=fundamental","pubTime":"2024-12-02 21:00","pubTimestamp":1733144413,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241202:nTUA78VN12:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2488394676","title":"Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-Life Extended Anti-Tl1a Antibodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2488394676","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488394676?lang=en_us&edition=fundamental","pubTime":"2024-12-02 21:00","pubTimestamp":1733144413,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241202:nTUA78VN12:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2486506947","title":"Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2486506947","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486506947?lang=en_us&edition=fundamental","pubTime":"2024-11-26 06:11","pubTimestamp":1732572660,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Nov. 25, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. , a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease , today announced that will participate in a fireside chat and investor meetings at the 7th Annual Evercore ISI HealthCONx Conference. Details of the fireside are as follows:. Tuesday, December 3, 2024, at 7:30 a.m. Eastern time. To access this webcast, please visit the \"Events & Presentations\" page within the Investors section of the Spyre website at ir.spyre.com. An archive of the webcast will be available for replay following the end of the conference.Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease  products by combining best-in-class antibody engineering, rational therapeutic combinations, and p","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OF7quuu2hXwKuKaISmsaxw--~B/aD05Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/b47b05eb14d0fa90aed91f47beedafa6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OF7quuu2hXwKuKaISmsaxw--~B/aD05Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/b47b05eb14d0fa90aed91f47beedafa6"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-participate-7th-annual-221100157.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-participate-7th-annual-221100157.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IBD","LENZ","SYRE"],"gpt_icon":0},{"id":"2484947785","title":"Sector Update: Health Care Stocks Lean Lower Premarket Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2484947785","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484947785?lang=en_us&edition=fundamental","pubTime":"2024-11-19 22:17","pubTimestamp":1732025868,"startTime":"0","endTime":"0","summary":"Health care stocks were leaning lower premarket Tuesday, with the iShares Biotechnology ETF  declining 0.5% and The Health Care Select Sector SPDR Fund  down 0.7%.Rocket Pharmaceuticals  shares were 3% higher, reversing a more than 2% decline from the previous day when the company said it will not begin patient enrollment for the phase 2 trial of its experimental RP-L301 gene therapy until next year as it is currently directing resources toward other programs.Spyre Therapeutics  shares were down more than 3% after the company priced an underwritten public offering of about 7.3 million shares of its common stock at $27.50 apiece for expected gross proceeds of $200 million.Medtronic  shares were 1% lower even after the company reported higher fiscal Q2 non-GAAP earnings and net sales.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B3T34201.USD","LU2271345857.HKD","LU0158827781.USD","RCKT","LU1989771016.USD","IBB","XLV","LU0158827948.USD","LU2023251221.USD","LU1989764748.USD","LU2028103732.USD","LU0070302665.USD","LU0496365809.HKD","LU2089284900.SGD","BK4581","LU0072461881.USD","BK4533","LU2111349929.HKD","LU0208291251.USD","IE00BQXX3C00.GBP","IE00BFXG1179.USD","LU0211326755.USD","LU1291159041.SGD","MDT","IE00BQXX3F31.USD","BK4588","IE00BQXX3D17.EUR","BK4566","BK4082","LU0211331839.USD","SYRE","BK4585","LU0162691827.USD","LU0320765489.SGD","BK4139","LU1571399168.USD","LU1989764664.SGD","LU2089283258.USD","LU0976567544.SGD","LU0211326839.USD"],"gpt_icon":0},{"id":"2484797990","title":"Spyre Therapeutics Prices $200 Million Common Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2484797990","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484797990?lang=en_us&edition=fundamental","pubTime":"2024-11-19 17:38","pubTimestamp":1732009088,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics  said late Monday it priced an underwritten public offering of about 7.3 million shares of its common stock at $27.50 per share for expected gross proceeds of $200 million.The company also granted the underwriters a 30-day option to buy up to an additional about 1.1 million shares. The offering is expected to close on or about Wednesday.Price: 28.41, Change: -0.26, Percent Change: -0.91","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","SYRE","BK4139"],"gpt_icon":0},{"id":"2484568019","title":"BRIEF-Spyre Therapeutics Announces Pricing Of $200 Mln Public Offering Of Common Stock At $27.50 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2484568019","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484568019?lang=en_us&edition=fundamental","pubTime":"2024-11-19 10:20","pubTimestamp":1731982823,"startTime":"0","endTime":"0","summary":"BRIEF-Spyre Therapeutics Announces Pricing Of $200 Mln Public Offering Of Common Stock At $27.50 Per ShareNov 18 (Reuters) - Spyre Therapeutics Inc SYRE.O:SPYRE THERAPEUTICS ANNOUNCES PRICING OF $200 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nTUABZSCV4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":58,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SYRE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-27","symbol":"SYRE","fiscalQuarterEnding":"2024/12","expectedEps":-1.1,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"post","actualEps":-0.81},{"market":"US","date":"2024-11-07","symbol":"SYRE","fiscalQuarterEnding":"2024/09","expectedEps":-0.8,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-1.36},{"market":"US","date":"2024-08-07","symbol":"SYRE","fiscalQuarterEnding":"2024/06","expectedEps":-0.9,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"post","actualEps":-0.86},{"market":"US","date":"2024-05-09","symbol":"SYRE","fiscalQuarterEnding":"2024/03","expectedEps":-0.9,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"post","actualEps":-1.2},{"market":"US","date":"2024-02-29","symbol":"SYRE","fiscalQuarterEnding":"2023/12","expectedEps":-0.48,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1709182800000,"reportTimeType":"post","actualEps":-2.28}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SYRE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SYRE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.25,"hold":0.0833,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":12,"updateTime":1744171200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SYRE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SYRE","date":"2025-05-02","current":-4.2479,"percent":0.568452,"low":-10.261647,"twenty":-7.361661,"median":-4.754422,"eighty":-3.465834,"high":-0.199399,"avg":-5.182357,"sd":2.037726,"marketCap":883639724},"quantilePoints":[{"date":"2023-12-01","current":-1.902619,"twenty":-1.228042,"median":-0.216176,"eighty":-0.20611,"marketCap":560191990},{"date":"2023-12-08","current":-2.024974,"twenty":-2.048834,"median":-1.98164,"eighty":-0.890753,"marketCap":596217199},{"date":"2023-12-15","current":-1.815535,"twenty":-2.023412,"median":-1.966856,"eighty":-1.735642,"marketCap":534551743},{"date":"2023-12-22","current":-2.106706,"twenty":-2.023412,"median":-1.950531,"eighty":-1.82549,"marketCap":620281740},{"date":"2023-12-29","current":-2.507984,"twenty":-2.09023,"median":-1.996425,"eighty":-1.840422,"marketCap":738430643},{"date":"2024-01-05","current":-2.757559,"twenty":-2.278228,"median":-2.002935,"eighty":-1.873937,"marketCap":811913497},{"date":"2024-01-12","current":-2.567931,"twenty":-2.588728,"median":-2.024974,"eighty":-1.89995,"marketCap":756080936},{"date":"2024-01-19","current":-2.66458,"twenty":-2.653814,"median":-2.09023,"eighty":-1.902486,"marketCap":784537532},{"date":"2024-01-26","current":-3.303198,"twenty":-2.742878,"median":-2.292052,"eighty":-1.915254,"marketCap":972567189},{"date":"2024-02-02","current":-3.16373,"twenty":-3.116751,"median":-2.567931,"eighty":-1.947266,"marketCap":931503241},{"date":"2024-02-09","current":-2.89825,"twenty":-3.138772,"median":-2.61809,"eighty":-1.978684,"marketCap":853337655},{"date":"2024-02-16","current":-2.760005,"twenty":-3.112591,"median":-2.66458,"eighty":-1.997649,"marketCap":812633917},{"date":"2024-02-23","current":-2.496973,"twenty":-3.08641,"median":-2.66458,"eighty":-2.000865,"marketCap":735188752},{"date":"2024-03-01","current":-3.357028,"twenty":-3.117974,"median":-2.696389,"eighty":-2.009323,"marketCap":988416432},{"date":"2024-03-08","current":-4.14553,"twenty":-3.186241,"median":-2.748383,"eighty":-2.021849,"marketCap":1404464057},{"date":"2024-03-15","current":-4.473117,"twenty":-3.315921,"median":-2.757559,"eighty":-2.032927,"marketCap":1515447446},{"date":"2024-03-22","current":-4.253303,"twenty":-3.374155,"median":-2.84075,"eighty":-2.069838,"marketCap":1440976508},{"date":"2024-03-28","current":-3.948124,"twenty":-3.948124,"median":-2.884793,"eighty":-2.09023,"marketCap":1337584817},{"date":"2024-04-05","current":-3.822655,"twenty":-3.997689,"median":-2.933117,"eighty":-2.106706,"marketCap":1295077328},{"date":"2024-04-12","current":-4.169482,"twenty":-4.017483,"median":-2.950857,"eighty":-2.22293,"marketCap":1412578691},{"date":"2024-04-19","current":-3.844264,"twenty":-4.019298,"median":-3.071974,"eighty":-2.361175,"marketCap":1302398285},{"date":"2024-04-26","current":-3.508242,"twenty":-4.017483,"median":-3.149049,"eighty":-2.496973,"marketCap":1188557401},{"date":"2024-05-03","current":-4.312212,"twenty":-4.026871,"median":-3.180093,"eighty":-2.505537,"marketCap":1460934345},{"date":"2024-05-10","current":-4.183809,"twenty":-4.050631,"median":-3.290964,"eighty":-2.507984,"marketCap":1417432578},{"date":"2024-05-17","current":-4.180278,"twenty":-4.096445,"median":-3.334395,"eighty":-2.567931,"marketCap":1522561849},{"date":"2024-05-24","current":-3.614061,"twenty":-4.096445,"median":-3.364368,"eighty":-2.569154,"marketCap":1316331249},{"date":"2024-05-31","current":-3.765942,"twenty":-4.092735,"median":-3.38639,"eighty":-2.608303,"marketCap":1371650246},{"date":"2024-06-07","current":-4.825529,"twenty":-4.146052,"median":-3.527045,"eighty":-2.61809,"marketCap":1757578310},{"date":"2024-06-14","current":-4.511821,"twenty":-4.180278,"median":-3.580903,"eighty":-2.629835,"marketCap":1643317946},{"date":"2024-06-21","current":-3.573485,"twenty":-4.180278,"median":-3.584639,"eighty":-2.648431,"marketCap":1301552501},{"date":"2024-06-28","current":-3.166361,"twenty":-4.18028,"median":-3.584639,"eighty":-2.659197,"marketCap":1153267940},{"date":"2024-07-05","current":-3.59161,"twenty":-4.180278,"median":-3.582547,"eighty":-2.666048,"marketCap":1308154211},{"date":"2024-07-12","current":-3.922049,"twenty":-4.1738,"median":-3.59161,"eighty":-2.678038,"marketCap":1428508461},{"date":"2024-07-15","current":-4.13816,"twenty":-4.171641,"median":-3.593701,"eighty":-2.681708,"marketCap":1507221157},{"date":"2024-08-02","current":-3.753344,"twenty":-4.169482,"median":-3.595793,"eighty":-2.685378,"marketCap":1367061777},{"date":"2024-08-09","current":-6.895906,"twenty":-4.180278,"median":-3.619566,"eighty":-2.707399,"marketCap":1282507443},{"date":"2024-08-16","current":-7.250942,"twenty":-4.233229,"median":-3.6476,"eighty":-2.720856,"marketCap":1348537529},{"date":"2024-08-23","current":-6.762084,"twenty":-4.253955,"median":-3.674487,"eighty":-2.748383,"marketCap":1257619180},{"date":"2024-08-30","current":-7.666062,"twenty":-4.345056,"median":-3.707046,"eighty":-2.757559,"marketCap":1425741938},{"date":"2024-09-06","current":-7.657869,"twenty":-4.411655,"median":-3.73151,"eighty":-2.757559,"marketCap":1424218166},{"date":"2024-09-13","current":-7.786586,"twenty":-4.705472,"median":-3.759643,"eighty":-2.757559,"marketCap":1448156979},{"date":"2024-09-20","current":-8.323214,"twenty":-4.847589,"median":-3.822655,"eighty":-2.759516,"marketCap":1547959640},{"date":"2024-09-27","current":-7.956335,"twenty":-5.135333,"median":-3.898142,"eighty":-2.824601,"marketCap":1479727208},{"date":"2024-10-04","current":-7.76742,"twenty":-6.713509,"median":-3.922049,"eighty":-2.854452,"marketCap":1444592598},{"date":"2024-10-11","current":-7.452562,"twenty":-6.898091,"median":-3.929227,"eighty":-2.87941,"marketCap":1386034914},{"date":"2024-10-18","current":-8.969358,"twenty":-7.252035,"median":-3.990015,"eighty":-2.895559,"marketCap":1668130191},{"date":"2024-10-25","current":-9.226721,"twenty":-7.3874,"median":-4.004712,"eighty":-2.923697,"marketCap":1715994732},{"date":"2024-10-31","current":-9.352664,"twenty":-7.525937,"median":-4.015348,"eighty":-2.933729,"marketCap":1739417806},{"date":"2024-11-08","current":-8.930417,"twenty":-7.599425,"median":-4.026871,"eighty":-2.936176,"marketCap":1919164435},{"date":"2024-11-15","current":-7.483663,"twenty":-7.650222,"median":-4.048996,"eighty":-2.944985,"marketCap":1608254249},{"date":"2024-11-22","current":-7.375771,"twenty":-7.638736,"median":-4.07743,"eighty":-3.008113,"marketCap":1585067940},{"date":"2024-11-29","current":-7.766414,"twenty":-7.641472,"median":-4.091807,"eighty":-3.046772,"marketCap":1669017834},{"date":"2024-12-06","current":-6.979665,"twenty":-7.646653,"median":-4.11994,"eighty":-3.06708,"marketCap":1499943921},{"date":"2024-12-13","current":-6.534387,"twenty":-7.641035,"median":-4.14553,"eighty":-3.107208,"marketCap":1404252782},{"date":"2024-12-20","current":-6.318577,"twenty":-7.622349,"median":-4.17488,"eighty":-3.133634,"marketCap":1357874868},{"date":"2024-12-27","current":-6.575363,"twenty":-7.605285,"median":-4.180282,"eighty":-3.151985,"marketCap":1413058715},{"date":"2025-01-03","current":-6.515264,"twenty":-7.602508,"median":-4.208519,"eighty":-3.16373,"marketCap":1400143347},{"date":"2025-01-10","current":-6.561704,"twenty":-7.598137,"median":-4.247699,"eighty":-3.165835,"marketCap":1410123404},{"date":"2025-01-17","current":-5.613781,"twenty":-7.595453,"median":-4.253955,"eighty":-3.16915,"marketCap":1206412821},{"date":"2025-01-24","current":-5.957984,"twenty":-7.590053,"median":-4.295985,"eighty":-3.182143,"marketCap":1280382658},{"date":"2025-01-31","current":-6.083645,"twenty":-7.581791,"median":-4.354133,"eighty":-3.191991,"marketCap":1307387519},{"date":"2025-02-07","current":-6.517996,"twenty":-7.571599,"median":-4.396289,"eighty":-3.243978,"marketCap":1400730409},{"date":"2025-02-14","current":-6.195648,"twenty":-7.5588,"median":-4.51381,"eighty":-3.285739,"marketCap":1331457069},{"date":"2025-02-21","current":-6.12189,"twenty":-7.543691,"median":-4.721977,"eighty":-3.295858,"marketCap":1315606390},{"date":"2025-02-28","current":-5.184327,"twenty":-7.527033,"median":-4.825529,"eighty":-3.30956,"marketCap":1078433261},{"date":"2025-03-07","current":-5.940106,"twenty":-7.521557,"median":-4.885482,"eighty":-3.331336,"marketCap":1235649000},{"date":"2025-03-14","current":-5.224396,"twenty":-7.515906,"median":-5.129477,"eighty":-3.352623,"marketCap":1086768364},{"date":"2025-03-21","current":-5.259167,"twenty":-7.500881,"median":-5.171542,"eighty":-3.359964,"marketCap":1094001432},{"date":"2025-03-28","current":-5.125877,"twenty":-7.471223,"median":-5.184327,"eighty":-3.369262,"marketCap":1066274674},{"date":"2025-04-04","current":-4.052513,"twenty":-7.451349,"median":-5.158757,"eighty":-3.380517,"marketCap":842995751},{"date":"2025-04-11","current":-3.456852,"twenty":-7.428767,"median":-5.125877,"eighty":-3.399507,"marketCap":719087442},{"date":"2025-04-17","current":-3.598835,"twenty":-7.393254,"median":-4.931737,"eighty":-3.419927,"marketCap":748622467},{"date":"2025-04-25","current":-4.326136,"twenty":-7.374839,"median":-4.857093,"eighty":-3.429694,"marketCap":899914125},{"date":"2025-05-02","current":-4.2479,"twenty":-7.361661,"median":-4.754422,"eighty":-3.465834,"marketCap":883639724}],"updateTime":1746269947949}}}